DEVELOPMENT OF ANTIBODY TO HEPATITIS C VIRUS (HCV) IN ACUTE AND CHRONIC NON-A, NON-B POSTTRANSFUSION HEPATITIS

被引：2

作者：

PASTORE, G

MONNO, L

MILELLA, M

SANTANTONIO, T

RUMI, MG

COLOMBO, M

GIANNELLI, A

FICO, C

DESTASIO, G

LATTANZIO, A

DERUVO, M

SFORZA, E

机构：

[1] Istituto di Malattie Infetttve, University of Bari, Bari, 70124, Piazza G. Cesare

[2] Istituto di Medicina Interna, University of Milan, Milan

[3] Ospedale 'Di Venere', Bari, Carbonara

来源：

EUROPEAN JOURNAL OF EPIDEMIOLOGY | 1992年 / 8卷 / 04期

关键词：

TAH; HCV; NANB HEPATITIS;

D O I：

10.1007/BF00146380

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The antibody to hepatitis C virus (anti-HCV) was measured by an immunoassay in 507 serum samples from 94 patients with acute and chronic post-transfusion non-A, non-B hepatitis (NANB) and in 436 healthy blood donors. Anti-HCV was found in 70.8 of patients with acute hepatitis, in 78.2 with chronic hepatitis, and in 1.4 of healthy blood donors. In acute hepatitis, anti-HCV appeared in the serum from 4 to 34 weeks after transfusion and from 1 to 30 weeks after the onset of the overt disease. Three patients with resolving hepatitis (21%) and 2 who developed chronic hepatitis (10%) lost anti-HCV during a mean follow-up period of 28 months. Among the 36 patients with chronic hepatitis, 2 (6%) lost anti-HCV after 12 months and 8 years respectively. These data indicate that in recent years HCV has been the major etiologic agent of acute and chronic transfusion-associated hepatitis (TAH) in our geographical area. The late appearance of anti-HCV from the onset of clinical and biochemical signs of acute hepatitis in more than 70% of patients limits the diagnostic utility of this assay for an earlier serological diagnosis of acute NANB hepatitis. Additional studies are required to determine the diagnostic significance of this antibody in chronic NANB hepatitis.

引用

页码：580 / 584

页数：5

共 21 条

[1]

Alter H.J., Transfusion associated non-A, non-B hepatitis. The first decade, Viral hepatitis and liver disease, pp. 537-542, (1988)

[2]

Alter H.J., Purcell R.H., Shih J.W., Detection of antibody to hepatitis C virus in prospectively followed recipients with acute and chronic non-A, non-B hepatitis, N. Engl. J. Med., 321, pp. 1494-1500, (1989)

[3]

Bradley D.W., Maynard J.E., Popper H., Post-transfusion non-A, non-B viral hepatitis physicochemical properties of two distinct agents, J. Infect. Dis., 148, pp. 254-265, (1983)

[4]

Bradley D.W., The agents of non-A, non-B viral hepatitis, J. Virol. Methods, 10, pp. 307-309, (1985)

[5]

Bruix J., Calvet X., Costa J., Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis, Lancet, 2, pp. 1004-1006, (1989)

[6]

Colombo M., Choo Q.L., Del Ninno E., Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma, Lancet, 2, pp. 1006-1008, (1989)

[7]

Dienstag J.L., Alter H.J., Non-A, non-B hepatitis. Evolving epidemiologic and clinical perspective, Semin. Liver Dis., 6, pp. 67-81, (1986)

[8]

Esteban H.L., Esteban R., Viladomiu L., Hepatitis C virus antibodies among risk groups in Spain, Lancet, 2, pp. 294-295, (1989)

[9]

Fagan E.A., Willia R., Non-A, non-B hepatitis, Semin. Liver Dis., 4, pp. 314-335, (1984)

[10]

Hopf U., Moller B., Kuther D., Long-term follow-up of post-transfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV), J. Hepatol., 10, pp. 69-76, (1990)

← 1 2 3 →